What is PleoPharma?
PleoPharma is a pharmaceutical enterprise dedicated to pioneering treatments for central nervous system disorders and substance abuse. With no current FDA-approved options for these conditions, the company aims to deliver innovative solutions to alleviate widespread suffering. PleoPharma's flagship program has demonstrated promising results, successfully concluding Phase 2 trials, and is supported by a collaborative network of healthcare professionals, researchers, and financial backers.
How much funding has PleoPharma raised?
PleoPharma has raised a total of $42.1M across 2 funding rounds:
Private Equity
$6.2M
Series B
$36M
Private Equity (2025): $6.2M, investors not publicly disclosed
Series B (2025): $36M, investors not publicly disclosed
What's next for PleoPharma?
The recent major enterprise-level funding positions PleoPharma for accelerated development and potential market entry. This strategic capital infusion is expected to fuel the advancement of its lead programs through late-stage clinical trials and regulatory submissions. The company's focus on addressing significant medical conditions with limited therapeutic alternatives suggests a strong potential for growth and impact in the pharmaceutical sector.
See full PleoPharma company page
